spacer
home > white papers > Biosimilars In Emerging Markets: Is It A Level Playing Field? - PRA Health Sciences (PRA)
WHITE PAPERS
logo_PRA_Health5.jpg

PRA Health Sciences (PRA)

phone +44 (118) 918-1000
email prahealthsciences@prahs.com
web http://www.prahs.com
email Green Park, 500 South Oak Way, Reading, RG2 6AD UK

Biosimilars In Emerging Markets: Is It A Level Playing Field?

Governments, healthcare payers, and social and health reforms, combined with the increased incidence of conditions such as cancer and diabetes are paving the way for increased uptake of biologic medicines in emerging markets. However, expensive biologic medicines can be prohibitive to many patients, creating a high level of unmet clinical need. At its best, the global expansion of biosimilars can mean a robust and steady supply of existing and new drugs reaching far-flung patient populations, but localized biosimilar drug developments, especially in China and India, combined with a lack of robust pharmacovigilance systems, threaten to derail the industry by putting patient health at risk.
Biosimilars In Emerging Markets: Is It A Level Playing Field?
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Distributor Oppurtunities

Have an appetite for success Want to expand your product portfolio Fancy being part of something special??
More info >>


White Papers

Soothing the Logistical Headache of Clinical Trials

Equilibrium Travel Management

As many as 30 per cent of subjects on phase three clinical studies drop out.  Gruelling schedules, high travel costs and time waiting for expense reimbursement can all be factors in these fall rates, and this can be very problematic, delaying or even leading to the cancellation of the trial.  It is crucial to keep subjects motivated, and through efficient travel and expense management, this can be achieved.
More info >>


Industry Events

Clinical Trials Europe | Partnerships, Outsourcing, Operations & Technology

27 August - 21 November 2019, Barcelona, Spain

On 19-21 November 2019, the clinical trial community's most influential stakeholders will be meeting in Barcelona to discuss the evolving landscape, honing in on what it takes to harness true value from partnerships, outsourcing, operations, technology and early clinical development, for a faster, more efficient route to market.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement